Physician profile
James P Longe
NPI 1093730129
$2,610.85
in general payments reported to CMS, 2019-2025
36 companies · $20.89 in 2025
The $20.89 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $174 · 2021: $300 · 2022: $639 · 2023: $691 · 2024: $414 · 2025: $20.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $655.27 | 2021-2024 | |
| Lilly USA, LLC | $267.13 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Abbott Laboratories | $208.04 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $169.26 | 2019-2023 | Shingrix, Arexvy, Pediarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.13 | 2019-2024 | Jardiance |
| Dynavax Technologies Corporation | $98.38 | 2019-2023 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $85.13 | 2019-2023 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $81.32 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $77.56 | 2022-2023 | |
| Pfizer INC. | $72.71 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.66 | 2020-2022 | |
| Horizon Therapeutics Plc | $50.55 | 2019-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $49.61 | 2020-2022 | |
| Gilead Sciences, INC. | $46.85 | 2019-2020 | |
| Amgen INC. | $45.05 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quidel Corporation | $40.85 | 2019 | |
| Corium, LLC | $40.27 | 2024 | Azstarys |
| Seqirus USA INC | $37.51 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $36.15 | 2021 | |
| Corcept Therapeutics | $32.13 | 2024 | Korlym |
| Genentech USA, INC. | $30.96 | 2020-2021 | |
| Boston Scientific Corporation | $29.54 | 2019-2020 | |
| Lucid Diagnostics INC. | $28.68 | 2021-2022 | |
| Novo Nordisk INC | $26.64 | 2021-2022 | |
| Cranial Technologies, INC | $25.69 | 2022-2023 | Doc Band |
| Merck Sharp & Dohme LLC | $17.79 | 2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Idorsia Pharmaceuticals US INC | $17.30 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.04 | 2022 | |
| Astellas Pharma US INC | $16.92 | 2019 | |
| Axsome Therapeutics, INC. | $14.59 | 2023 | Auvelity |
| Sanofi-Aventis U.S. LLC | $13.91 | 2020 | |
| Hologic Sales and Service, LLC | $13.88 | 2022 | |
| Endo Pharmaceuticals INC. | $13.39 | 2019 | |
| Axonics, INC. | $13.20 | 2022 | |
| Allergan, INC. | $13.09 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Longe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.